2024 Sparsentan New Drug Buying Guide

With the continuous advancement of medical technology, specific drugs for specific diseases have gradually come into public view. Spasentan (sparsentan), as a new drug for the treatment of primary IgA nephropathy (IgAN), has attracted much attention from patients and the medical community because of its unique pharmacological mechanism and significant therapeutic effect. In 2024, we will provide a new drug purchase guide for patients who need to purchase sparsentane.

1. Introduction to Sparsentine

Sparsentan is a dual endothelin angiotensin receptor antagonist (DEARA), mainly used to treat adult patients with primary IgAN who are at risk of rapid disease progression and have a urine protein to creatinine ratio (UPCR) ≥1.5g/g. It reduces proteinuria levels and protects kidney function by blocking two pathways related to the progression of IgA nephropathy. Always talk to your doctor before taking this medication to make sure spaxentan is appropriate for your condition.

2. Drug purchasing channels

Since sparsentane is not yet available in China, patients can purchase it through overseas channels. The generic version of Sparsentan produced by Lucius Pharmaceuticals in Laos is 400mg*30 tablets/box, and each box sells for about more than 7,000. Patients can consult professional overseas medical service agencies to ensure the authenticity and effectiveness of the medicine. These institutions usually have direct ties with pharmaceutical manufacturers and can provide patients with safe and reliable sources of medicines, as well as convenient services such as direct delivery to their homes.

3. Precautions when purchasing medicines

1. Follow the doctor's instructions: Sparsentan is a prescription drug. Patients should consult a doctor before use and follow the doctor's instructions. Never adjust your dose or stop taking it on your own.

2. Pay attention to drug storage: After receiving the drug, patients should pay attention to the way the drug is stored and kept to avoid problems such as moisture and deterioration of the drug that affect the treatment effect.

In short, as a new drug for the treatment of primary IgA nephropathy, sparsentan shows significant advantages in terms of efficacy and safety. When purchasing and using drugs, patients should choose formal channels, follow doctor's instructions, and pay attention to the storage and safekeeping of drugs.